| Manufacturer | Eli Lilly and Company | Novo Nordisk |
| Pricing | Manufacturer self-pay options: - Starting Price: $299/month for the 2.5 mg starting dose through eligible manufacturer self-pay options.
- Higher Doses: Approximately $399–$449/month under qualifying self-pay programs, depending on dosage and refill requirements.
- Eligibility: Pricing depends on delivery device, dosage, and manufacturer program requirements.
Retail prices may be higher. | Manufacturer self-pay offers: - Introductory Offer: Starting at $199/month for eligible new injection patients during a limited promotional period.
- Standard Injection Offers: Approximately $349/month for standard injection doses through eligible programs.
- Oral Formulation: Self-pay offers starting at $149/month, with higher costs for certain doses.
Retail prices may be higher. |
| Insurance Coverage | - Commercial Insurance: Some plans cover Zepbound for eligible patients with obesity or other approved indications.
- Prior Authorization: Medical eligibility and documentation may be required.
- Medicare: Coverage depends on the approved indication, applicable program rules, and individual plan.
| - Commercial Insurance: Some plans cover Wegovy for qualifying weight-management or other approved indications.
- Medicare Part D: Coverage may be available for certain medically eligible patients under approved indications and applicable rules.
- Prior Authorization: Coverage may require documentation of cardiovascular disease, obesity, or other qualifying conditions.
|
| Main Purpose | Long-term weight loss and weight maintenance in eligible adults with obesity or overweight. | Long-term weight loss and weight maintenance in eligible adults, with injectable treatment also approved for adolescents aged 12 years and older with obesity. |
| Secondary Purposes | - Sleep Apnea: Treat moderate to severe obstructive sleep apnea in adults with obesity.
- Metabolic Health: May improve blood sugar regulation and other metabolic measures.
| - Cardiovascular Protection: Reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.
- Liver Disease: Wegovy injection treats certain adults with noncirrhotic MASH and moderate to advanced liver fibrosis under accelerated approval.
|
| Active Ingredient | Tirzepatide, a dual GIP and GLP-1 receptor agonist. | Semaglutide, a GLP-1 receptor agonist. |
| Benefits | - Weight Loss: Produces substantial average weight reduction, exceeding injectable Wegovy in a direct clinical trial.
- Appetite Regulation: Reduces hunger and food intake.
- Metabolic Health: May improve weight-related metabolic measures.
- Sleep Apnea: Reduces obstructive sleep apnea severity in eligible adults with obesity.
| - Weight Management: Produces clinically meaningful weight loss and helps maintain weight reduction.
- Cardiovascular Health: Reduces major cardiovascular events in eligible adults with established cardiovascular disease.
- Liver Health: Wegovy injection may improve MASH and liver fibrosis in qualifying adults.
- Administration Options: Offers injectable and oral formulations for eligible patients.
|
| Potential Health Risks | - Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Gastrointestinal Reactions: Potentially severe digestive symptoms.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
| - Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Eye Complications: Possible worsening of diabetic retinopathy in patients with diabetes.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
|
| Weight Loss Potential | Approximately 20.2% average body-weight reduction after 72 weeks in the SURMOUNT-5 head-to-head trial involving adults with obesity or qualifying overweight without diabetes. Zepbound produced greater average weight loss than injectable Wegovy under the conditions studied. | Approximately 13.7% average body-weight reduction after 72 weeks in the same SURMOUNT-5 trial. Wegovy remains an effective weight-management treatment, although average weight loss was lower than Zepbound in this comparison. Results vary by dosage, formulation, and patient characteristics. |
| Administration | - Injection: Subcutaneous injection once weekly.
- Injection Sites: Abdomen, thigh, or upper arm.
- Available Forms: Different injection devices and vial presentations.
| - Injection: Subcutaneous injection once weekly.
- Oral Tablet: Once-daily oral formulation with specific administration instructions.
- Injection Sites: Abdomen, thigh, or upper arm.
|
| Dosing Considerations | - Starting Dose: Typically 2.5 mg weekly.
- Dose Escalation: Gradual increases according to response and tolerability.
- Maintenance Dose: Usually 5 mg, 10 mg, or 15 mg weekly for weight management.
| - Starting Injection Dose: Typically 0.25 mg weekly.
- Dose Escalation: Gradual increases, with 2.4 mg weekly the usual recommended injection maintenance dose for weight management.
- Oral Dosing: Starts at 1.5 mg daily and increases according to a separate schedule, with 25 mg daily the recommended maintenance dose.
|
| Who May Benefit Most? | Adults with obesity or qualifying overweight who prioritize greater average weight loss, including eligible patients with obesity-related moderate to severe obstructive sleep apnea. | Adults with obesity or qualifying overweight who also have established cardiovascular disease, eligible adults with MASH, and patients who may benefit from an oral formulation. Wegovy injection may also benefit adolescents aged 12 years and older with obesity. |
| How Fast Does It Work? | - Appetite: Changes may begin within the first several weeks.
- Initial Weight Loss: May become noticeable within several weeks.
- Substantial Weight Loss: Generally develops over several months, with the SURMOUNT-5 trial assessing outcomes at 72 weeks.
| - Appetite: Changes may begin within the first several weeks.
- Initial Weight Loss: May become noticeable within several weeks.
- Substantial Weight Loss: Typically develops gradually over several months, with clinical trials assessing outcomes over extended treatment periods.
|
| Potential Side Effects | - Digestive: Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion.
- Other Effects: Fatigue and injection-site reactions.
- Timing: Gastrointestinal symptoms frequently occur during dose escalation.
| - Digestive: Nausea, vomiting, diarrhea, constipation, abdominal pain, and indigestion.
- Other Effects: Headache, fatigue, and possible injection-site reactions with injectable treatment.
- Timing: Gastrointestinal symptoms frequently occur when starting treatment or increasing dosage.
|